Mayo Clinic Validates AI Tool Poised to Reshape Mental Healthcare

SAN RAMON, CA – July 28, 2026 – MedLink Global, a health technology firm born out of UC Berkeley, has announced that its AI-assisted MedLink Psychiatric tool is now a qualified solution on the prestigious Mayo Clinic Platform. This milestone represents more than just a new software listing; it signals a significant validation for a technology aiming to solve some of the most persistent challenges in mental healthcare: fragmented patient data, inconsistent evaluations, and a deepening workforce crisis. By integrating its measurement-based solution into one of healthcare's leading technology ecosystems, MedLink Global is taking a major step toward its goal of transforming psychiatry into a more measurable, data-driven discipline.

The company was founded by a multidisciplinary team, including CEO and co-founder Ran Yang-Chawla, renowned psychiatrist and clinical researcher Dr. Christoph U. Correll, and psychometric expert Dr. Mark Blais. Their collective vision addresses a critical gap in modern medicine. “Despite tremendous advances in medicine, psychiatry has long been constrained by fragmented information and a lack of structured longitudinal data,” said Ran Yang-Chawla. “By integrating our Psychiatric Intake and MaiNDS™ modules with Mayo Clinic Platform, we are helping healthcare organizations build the data foundation needed for more consistent, evidence-based mental healthcare.”

The "Nutrition Label" for Digital Health

For any digital health startup, earning the trust of clinicians and large health systems is a monumental hurdle. MedLink Global's qualification by the Mayo Clinic Platform provides a powerful solution to this challenge. The platform's Solutions Studio subjects potential partners to what is described as a "rigorous, proprietary qualification process" that functions as a seal of approval, assuring providers that a tool is not just innovative, but also safe, effective, and ready for clinical deployment.

This rigorous vetting process goes far beyond a simple technical check. According to the platform's public materials, solutions are meticulously evaluated for their intended use, clinical utility, psychometric validation, and algorithmic performance across diverse patient populations. This ensures that any qualified technology is, in the words of one platform leader, "fair, appropriate, valid, and effective." This validation is crucial in a market flooded with digital health solutions of varying quality. As Steve Bethke, vice president of Solution Developer Market at Mayo Clinic Platform, stated, the program is designed to provide "transparency and credibility, and enabling the adoption of transformative health technologies.​"

One source close to the platform likened the qualification to a "nutrition label" for digital tools, allowing healthcare administrators and clinicians to make informed decisions with confidence. This process is designed to "break through the credibility and trust barrier" that often stalls the adoption of promising new technologies. MedLink Global's journey with Mayo Clinic began even earlier, through its participation in the Mayo Clinic Platform_Accelerate program. This collaborative effort allowed the company to develop and refine its AI models using millions of de-identified clinical data points, further strengthening the solution's foundation before it even reached the qualification stage.

Structuring the Mind: How the Technology Works

At the heart of MedLink Global's innovation is a two-part system designed to bring structure and efficiency to the psychiatric evaluation process. The MedLink Psychiatric tool combines an AI-assisted Psychiatric Intake Module with the MaiNDS™ Assessment Module. Together, they shift the burden of structured data collection from the limited time of a clinical visit to the pre-visit setting, providing clinicians with a comprehensive patient profile before the appointment even begins.

This approach directly tackles the historical reliance on fragmented, episodic information and subjective patient recall that can make psychiatric diagnosis and treatment a lengthy process of trial and error. The MaiNDS™ assessment, which is based on the extensive research of psychometric expert and co-founder Dr. Mark Blais, provides a comprehensive, broadband framework for measuring psychiatric symptom severity and complexity across multiple diagnostic domains. Instead of a free-form interview, the system guides the patient through a structured process, capturing data that is consistent, quantifiable, and trackable over time.

The efficiency gains are potentially transformative. MedLink Global suggests its AI-guided intake can reduce the time spent on initial evaluations from a typical 80 minutes down to just 15, potentially saving a single clinician more than six hours of documentation and data-gathering work each week. This saved time can be redirected toward direct patient interaction and complex decision-making. Furthermore, the platform includes a "treatment co-pilot," an AI feature trained on a vast dataset from Mayo Clinic, which offers personalized treatment suggestions. This moves the field closer to the goal of precision psychiatry, where care is tailored to an individual's specific clinical profile. However, the company is clear about the technology's role. The platform is designed to "support, not replace, clinical judgment," generating structured summaries and profiles that empower clinicians, rather than supplanting their expertise.

A New Paradigm for a Strained System

The qualification of the MedLink Psychiatric tool arrives at a critical moment for mental healthcare. The industry is grappling with unprecedented demand for services, exacerbated by a severe and growing shortage of qualified mental health professionals. By streamlining clinical workflows and reducing the administrative burden that contributes to clinician burnout, AI-driven tools like MedLink's offer a tangible way to mitigate the impact of these workforce shortages. As CEO Ran Yang-Chawla noted, the goal is to use AI to "amplify human expertise" and scale excellence in care delivery.

This technology is also a catalyst for the broader adoption of measurement-based care (MBC) in psychiatry—a paradigm where standardized data is systematically collected and used to guide clinical decisions and track outcomes. While common in other medical fields, MBC has been slow to take hold in mental health due to the lack of tools for efficient, structured data collection. By integrating this capability directly into clinical workflows and EHR systems, MedLink Global is building the infrastructure necessary for MBC to become standard practice.

The benefits extend across the healthcare ecosystem. For patients, this new approach can lead to faster, more accurate diagnoses, more personalized and effective treatment plans, and a clearer understanding of their own progress over time. For health systems, it provides a pathway to standardized care, improved quality metrics, and better resource allocation. The tool's utility is not confined to psychiatric specialists; it is also designed for use in primary care, neurology, pain management, and other specialties where neuropsychiatric symptoms frequently present but are often difficult to assess. This broad applicability promises to improve the identification and management of mental health conditions across the entire spectrum of patient care. The rigorous validation from an institution like Mayo Clinic is a critical step in building the necessary trust for this new paradigm to take root, assuring both providers and patients that the future of mental healthcare is not only innovative but also responsible and evidence-based.